Tetrahydroxylated bile acids prevents malignant progression of Barret esophagus in vitro by inhibiting the interleukin-1β-nuclear factor kappa-B pathway

doi:10.3748/wjg.v31.i29.107066

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (177)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

HTML

103

Figures (1-7)

Sum=155

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=13

Aug 7, 2025 (publication date) through Aug 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Aug 7, 2025; 31(29): 107066
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.107066

Full Size Figure Download Figure

Figure 1 Scheme of cultivation of adult tissue-resident stem cells isolated from Barrett esophagus clinical biopsies and cytotoxicity investigation using different concentrations of deoxycholic acid, tetrahydroxylated bile acids and their combinations. BE-ASCs: Barrett esophagus clinical biopsies; DCA: Deoxycholic acid; THBA: Tetrahydroxylated bile acids.

Citation: Mamchur A, Duggan S, Xue H, Niu XJ, Wang YZ, Ma ZW, Kelleher D, Ling V, Gao ZH. Tetrahydroxylated bile acids prevents malignant progression of Barret esophagus in vitro by inhibiting the interleukin-1β-nuclear factor kappa-B pathway. World J Gastroenterol 2025; 31(29): 107066
URL: https://www.wjgnet.com/1007-9327/full/v31/i29/107066.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i29.107066